Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Pediatric aplastic anemia (AA) patients undergoing umbilical cord blood transplantation (UCBT) face outcomes that are closely tied to the infused cell dose. While recommended CD34⁺ cell doses have been established for hematologic malignancies, no clear standard exists for AA, leaving an important gap in clinical decision-making.
Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Allogeneic hematopoietic stem cell transplantation (HSCT) in elderly patients with hematologic malignancies remains associated with substantial treatment-related risks. Choosing among haploidentical, matched sibling, and matched unrelated donors remains challenging due to the lack of robust head-to-head comparative data.
Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL

Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL

Although CD19 CAR-T therapy achieves high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), relapse driven by CD19 antigen loss poses a major challenge for MRD monitoring and long-term disease management. Identifying more stable biomarkers has therefore become essential for improving response assessment and prognostic evaluation.
Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts worldwide to present advances in hematopoietic stem cell transplantation and cellular therapies, fostering innovation in clinical practice.
Highlights from the EBMT Annual Meeting / Autologous Hematopoietic Stem Cell Transplantation Combined with CAR-T Therapy Significantly Improves Progression-Free Survival in Relapsed/Refractory Central Nervous System Lymphoma

Highlights from the EBMT Annual Meeting / Autologous Hematopoietic Stem Cell Transplantation Combined with CAR-T Therapy Significantly Improves Progression-Free Survival in Relapsed/Refractory Central Nervous System Lymphoma

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT gathers experts worldwide to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapies, fostering innovation in clinical practice and advancing the field.
Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

The 52nd EBMT Annual Meeting will take place in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential international meetings in hematopoietic stem cell transplantation and cellular therapy, the congress brings together more than 6,000 experts from over 90 countries and regions to discuss advances in basic research, clinical translation, optimization of transplant strategies, and innovation in cellular therapies.
Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the central challenges in the treatment of acute leukemia. Minimal residual disease (MRD) positivity serves as an important early warning signal for relapse, and identifying effective interventions during this critical window has become a major focus of clinical research.
Highlights from the EBMT Annual Meeting CD19 CAR-T Therapy in Transformed Follicular Lymphoma: A Real-World Cohort of 43 Patients 

Highlights from the EBMT Annual Meeting CD19 CAR-T Therapy in Transformed Follicular Lymphoma: A Real-World Cohort of 43 Patients 

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts from around the world to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapies, driving innovation in clinical practice.
Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the leading international forums in hematology, the meeting brings together experts worldwide to present advances in transplantation, cellular immunotherapy, and complication management, and remains an important platform shaping the future of hematologic treatment.